A Harvard Medical School team has found a cyclin dependent kinase 7 inhibitor that covalently binds a cysteine outside the enzyme's kinase domain and suppresses leukemia in mice. Syros Pharmaceuticals has licensed the compound, dubbed THZ1, for its preclinical CDK7 inhibitor program.